Overview

• Shares listed at Rs 620 on NSE and Rs 620.10 on BSE on October 16, a 27.8% premium to the Rs 485 issue price.
• The offer drew overall subscription of 103.90 times, with QIBs at 130.26x, NIIs at 97.61x, retail at 35.47x, and employees at 16.80x.
• Proceeds comprised a Rs 500 crore fresh issue and a Rs 877.50 crore offer for sale, within a price band of Rs 461–485 and a lot size of 30 shares.
• Allotment was finalised on October 14 with demat credits slated for October 15, and a retail lot at the listing price yielded roughly Rs 4,053 in gains per media calculations.
• Thane-based Rubicon Research develops differentiated formulations with three Indian manufacturing facilities and 72 active ANDA/NDA approvals, with Axis Capital, JM Financial, and IIFL as bookrunners and MUFG Intime India as registrar.